WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,656,070.
The patent covers the novel application of real-time accelerometer measurements to control transcutaneous electrical nerve stimulation. This core technology enables several advanced Quell® features, including automatic adjustment of stimulation while the user is sleeping. Quell is the only transcutaneous electrical nerve stimulator on the market that incorporates advanced sensor technologies, such as accelerometers, to regulate neurostimulation and optimize relief from chronic pain.
"We are pleased to have received this latest patent for Quell Wearable Pain Relief Technology™. Quell is unique among commercial transcutaneous electrical nerve stimulation devices in that it uses sensors to automatically adjust stimulation for optimal comfort and pain relief," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "With this patent, we have further strengthened our leadership position in wearable pain relief technology.”
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.